Immuneering (IMRX) Change in Accured Expenses (2020 - 2026)
Immuneering (IMRX) posted quarterly Change in Accured Expenses of -$247323.0 for Q1 2026, down 39.62% year-over-year from -$409643.4 in Q1 2025, and down 216.98% quarter-over-quarter from $211424.0 in Q4 2025.
Immuneering (IMRX) Change in Accured Expenses (2020 - 2026) Analysis & Trends
Immuneering's Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$247323.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 39.62% year-over-year to -$247323.0; the TTM figure through Mar 2026 stood at -$12341.0 (down 137.51% YoY), while the FY2025 annual figure was $57848.0, up 321.6% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$247323.0, down from $211424.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $2.1 million in Q2 2023, with the low at -$2.2 million in Q1 2022.
- The 5-year median for Change in Accured Expenses is $66608.0 (2024), against an average of $29350.7.
- The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses soared 2432.12% in 2022, then tumbled 521.93% in 2025.
- Immuneering's Change in Accured Expenses stood at $430006.0 in 2022, then surged by 240.5% to $1.5 million in 2023, then plunged by 88.12% to $174008.0 in 2024, then climbed by 21.5% to $211424.0 in 2025, then sank by 216.98% to -$247323.0 in 2026.
- Business Quant data shows IMRX's Change in Accured Expenses at -$247323.0 in Q1 2026, $211424.0 in Q4 2025, and $304594.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | 1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Mn |
| Jun 30, 2026 | 1.03 Mn |
| Mar 31, 2026 | -247,323.00 |
| Mar 31, 2026 | -247,323.00 |
| Dec 31, 2025 | 211,424.00 |
| Dec 31, 2025 | 211,424.00 |
| Sep 30, 2025 | 304,594.00 |
| Sep 30, 2025 | 304,594.00 |
| Jun 30, 2025 | -281,036.00 |
| Jun 30, 2025 | -281,036.00 |
| Mar 31, 2025 | -177,134.00 |
| Mar 31, 2025 | -177,134.00 |
| Dec 31, 2024 | 174,008.00 |
| Dec 31, 2024 | 174,008.00 |
| Sep 30, 2024 | -30,585.00 |
| Sep 30, 2024 | -30,585.00 |
| Jun 30, 2024 | 66,608.00 |
| Jun 30, 2024 | 66,608.00 |
| Mar 31, 2024 | -236,136.00 |
| Mar 31, 2024 | -236,136.00 |